Prognostic Implications of MYBL2 in Resected Chinese Gastric Adenocarcinoma Patients

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2019 Feb 28

PMID 30809094

Citations 9

Authors

Yongxu Jia

Yaping Gao

Jing Li

Zhiwei Chang

Jie Yan

Yanru Qin

Affiliations

Soon will be listed here.

Abstract

Background And Aim: Gastric cancer (GC), a malignant tumor worldwide, is mostly diagnosed at an advanced stage. We selected the oncogene encoding transcription factors MYBL2 to investigate the connection between MYBL2 expression and GC prognosis.

Materials And Methods: MYBL2 mRNA and protein expression were measured by real-time PCR and immunohistochemistry, respectively. The relationship between MYBL2 protein expression and survival time was estimated by the Kaplan-Meier analysis. Cox proportional hazards model was used to evaluate the prognostic impact of MYBL2 expression.

Results: The overexpression of MYBL2 was related to tumor cell differentiation, Lauren type, and metastasis of lymph nodes (<0.05). In the MYBL2 overexpression group, the median disease free survival was even poorer (=0.000) and it comes to median overall survival (=0.000). The study showed that MYBL2 expression was an independent hazard for disease free survival (=0.004).

Conclusion: The results of this study suggest that MYBL2 could indicate a promisingly prognostic biomarker for GC patients.

Citing Articles

E2F1 and E2F7 regulate gastric cancer cell proliferation, respectively, through transcriptional activation and transcriptional repression of MYBL2.

Wu T, Jiang F, Wu F, Zheng G, Li Y, Wu L J Biol Chem. 2024; 301(1):108027.

PMID: 39613162 PMC: 11731210. DOI: 10.1016/j.jbc.2024.108027.

Molecular pathways in glioblastoma-derived stem cells to identify effective drug agents: A bioinformatics study.

Mirzaei T, Sheikholeslami S, Bereimipour A, Jalili A, Zali A, Sharbati S J Family Med Prim Care. 2022; 11(6):2856-2864.

PMID: 36119333 PMC: 9480797. DOI: 10.4103/jfmpc.jfmpc_1436_21.

[High expression of MYBL2 promotes progression and predicts a poor survival outcome of prostate cancer].

Yang M, Zhu X, Shen Y, He Q, Qin Y, Shao Y Nan Fang Yi Ke Da Xue Xue Bao. 2022; 42(8):1109-1118.

PMID: 36073208 PMC: 9458535. DOI: 10.12122/j.issn.1673-4254.2022.08.01.

MYBL2 accelerates epithelial-mesenchymal transition and hepatoblastoma metastasis via the Smad/SNAI1 pathway.

Wei M, Yang R, Ye M, Zhan Y, Liu B, Meng L Am J Cancer Res. 2022; 12(5):1960-1981.

PMID: 35693071 PMC: 9185624.

Down-Regulation of CIDEA Promoted Tumor Growth and Contributed to Cisplatin Resistance by Regulating the JNK-p21/Bad Signaling Pathways in Esophageal Squamous Cell Carcinoma.

Gao Y, Li L, Yan J, Hou X, Jia Y, Chang Z Front Oncol. 2021; 10:627845.

PMID: 33614508 PMC: 7888273. DOI: 10.3389/fonc.2020.627845.

References

Cervellera M, Raschella G, Santilli G, Tanno B, Ventura A, Mancini C . Direct transactivation of the anti-apoptotic gene apolipoprotein J (clusterin) by B-MYB. J Biol Chem. 2000; 275(28):21055-60. DOI: 10.1074/jbc.M002055200. View

Zondervan P, Wink J, Alers J, Ijzermans J, Schalm S, de Man R . Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias. J Pathol. 2000; 192(2):207-15. DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH690>3.0.CO;2-#. View

Mao X, Orchard G, Lillington D, Russell-Jones R, Young B, Whittaker S . Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. Blood. 2002; 101(4):1513-9. DOI: 10.1182/blood-2002-08-2434. View

Bar-Shira A, Pinthus J, Rozovsky U, Goldstein M, Sellers W, Yaron Y . Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft. Cancer Res. 2002; 62(23):6803-7. View

Sotiriou C, Neo S, McShane L, Korn E, Long P, Jazaeri A . Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A. 2003; 100(18):10393-8. PMC: 193572. DOI: 10.1073/pnas.1732912100. View

Korenjak M, Taylor-Harding B, Binne U, Satterlee J, Stevaux O, Aasland R . Native E2F/RBF complexes contain Myb-interacting proteins and repress transcription of developmentally controlled E2F target genes. Cell. 2004; 119(2):181-93. DOI: 10.1016/j.cell.2004.09.034. View

Zhu W, Giangrande P, Nevins J . E2Fs link the control of G1/S and G2/M transcription. EMBO J. 2004; 23(23):4615-26. PMC: 533046. DOI: 10.1038/sj.emboj.7600459. View

Lewis P, Beall E, Fleischer T, Georlette D, Link A, Botchan M . Identification of a Drosophila Myb-E2F2/RBF transcriptional repressor complex. Genes Dev. 2004; 18(23):2929-40. PMC: 534653. DOI: 10.1101/gad.1255204. View

Lang G, Gombert W, Gould H . A transcriptional regulatory element in the coding sequence of the human Bcl-2 gene. Immunology. 2004; 114(1):25-36. PMC: 1782053. DOI: 10.1111/j.1365-2567.2004.02073.x. View

10.

Arsura M, Introna M, Passerini F, Mantovani A, Golay J . B-myb antisense oligonucleotides inhibit proliferation of human hematopoietic cell lines. Blood. 1992; 79(10):2708-16. View

11.

Ahlbory D, Appl H, Lang D, Klempnauer K . Disruption of B-myb in DT40 cells reveals novel function for B-Myb in the response to DNA-damage. Oncogene. 2005; 24(48):7127-34. DOI: 10.1038/sj.onc.1208869. View

12.

Sala A . B-MYB, a transcription factor implicated in regulating cell cycle, apoptosis and cancer. Eur J Cancer. 2005; 41(16):2479-84. DOI: 10.1016/j.ejca.2005.08.004. View

13.

Thorner A, Hoadley K, Parker J, Winkel S, Millikan R, Perou C . In vitro and in vivo analysis of B-Myb in basal-like breast cancer. Oncogene. 2008; 28(5):742-51. PMC: 2636852. DOI: 10.1038/onc.2008.430. View

14.

Knight A, Notaridou M, Watson R . A Lin-9 complex is recruited by B-Myb to activate transcription of G2/M genes in undifferentiated embryonal carcinoma cells. Oncogene. 2009; 28(15):1737-47. DOI: 10.1038/onc.2009.22. View

15.

Mannefeld M, Klassen E, Gaubatz S . B-MYB is required for recovery from the DNA damage-induced G2 checkpoint in p53 mutant cells. Cancer Res. 2009; 69(9):4073-80. DOI: 10.1158/0008-5472.CAN-08-4156. View

16.

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

17.

Gualdrini F, Corvetta D, Cantilena S, Chayka O, Tanno B, Raschella G . Addiction of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop. Oncotarget. 2011; 1(4):278-288. PMC: 3248110. DOI: 10.18632/oncotarget.138. View

18.

Kurokawa K, Tanahashi T, Iima T, Yamamoto Y, Akaike Y, Nishida K . Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells. J Gastroenterol. 2012; 47(8):883-95. DOI: 10.1007/s00535-012-0547-6. View

19.

Iida M, Brand T, Campbell D, Li C, Wheeler D . Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor. Oncogene. 2012; 32(6):759-67. PMC: 3381861. DOI: 10.1038/onc.2012.90. View

20.

Fassan M, Baffa R, Kiss A . Advanced precancerous lesions within the GI tract: the molecular background. Best Pract Res Clin Gastroenterol. 2013; 27(2):159-69. DOI: 10.1016/j.bpg.2013.03.009. View